Timothy Flannery
Pediatric Endocrinology · Orange, CANPI 1871662304
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,183 of the $31,773 with a category attached, or 73.0%. Ascendis Pharma Endocrinology Inc accounts for 83.3% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $12,054 and has fallen 91.8% since, to $983 in 2025. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $145.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$26K
- Novo Nordisk AS$1K
- Novo Nordisk$711
- AbbVie$359
- Tandem Diabetes Care, Inc.$246
- Kyowa Kirin, Inc.$218
- plus $2K from 30 others
Across 203 payments — averaging $857.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$123K
- Ascendis Pharma Endocrinology Inc$51K
What the payments were for
- Speaking & faculty fees$23,18373%
- Travel & lodging$2,4348%
- Food & beverage$5,90819%
- Education$2491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 68 | $26,455 |
| Novo Nordisk AS | 4 | $1,389 |
| Novo Nordisk | 14 | $711 |
| AbbVie | 20 | $359 |
| Tandem Diabetes Care, Inc. | 10 | $246 |
| Kyowa Kirin, Inc. | 6 | $218 |
| Lilly USA, LLC | 10 | $202 |
| Tolmar, Inc. | 7 | $191 |
| Abbott | 4 | $181 |
| Dexcom, Inc. | 9 | $172 |
| Neurocrine Biosciences, Inc. | 5 | $156 |
| Arbor Pharmaceuticals, Inc. | 8 | $152 |
| Pfizer | 7 | $140 |
| Medtronic(2 entities) | 6 | $139 |
| Xeris Pharmaceuticals, Inc. | 5 | $113 |
| Azurity Pharmaceuticals, Inc. | 4 | $89 |
| Rhythm Pharmaceuticals, Inc. | 3 | $86 |
| Tolmar Pharmaceuticals, Inc. | 2 | $84 |
| Ipsen Biopharmaceuticals, Inc | 2 | $84 |
| Insulet Corporation | 3 | $75 |
| Amgen | 3 | $74 |
| Ultragenyx Pharmaceutical Inc. | 2 | $60 |
| Sandoz | 1 | $49 |
| Eton Pharmaceuticals, Inc. | 2 | $49 |
| Ascensia Diabetes Care US Inc. | 2 | $44 |
| BD | 1 | $42 |
| Chiesi USA, Inc. | 1 | $30 |
| Sequel Med Tech, LLC | 1 | $26 |
| Biomarin Pharmaceutical Inc. | 1 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Travere Therapeutics, Inc. | 2 | $22 |
| Sanofi | 1 | $18 |
| Vistapharm, Inc. | 1 | $18 |
| Senseonics, Incorporated | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,773 in reported general payments places this provider in the 90th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Orange
- Lynda PolgreenOrange$167K
- Himala KashmiriOrange$5K
- Daina DreimaneOrange$3K
- Nikita ForghaniOrange$3K
- Lien TrinhOrange$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Kevin KaisermanWest Covina$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.